title: Exploiting RNA as a new biomolecular target for synthetic polyamines.
abstract: Anticancer chemotherapy is strongly hampered by the low therapeutic index of most anticancer drugs and the development of chemoresistance. Therefore, there is a continued need for the identification of new molecular targets in order to selectively hit cancer cells. RNA has been recently validated as a cancer target by the use of different specific ligands and/or by different agents able to destroy its diverse forms. The ability of synthetic polyamines to interact and to alter the RNA structure has been already reported. In the present paper the interaction and the ability to damage RNA structure by several synthetic polyamines were evaluated and quantified by microfluid capillary electrophoresis. This technique allowed us to visualize both the RNA impairment through different electropherograms and to assess the RNA integrity number. Finally, the ability to discriminate between RNA and DNA by these synthetic polyamines was also evaluated.
authors.affiliation: Department of Pharmacy and BioTechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Minarini
authors.forename: Andrea
authors.initials: A
authors.lastname: Milelli
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Tumiatti
authors.forename: Michela
authors.initials: M
authors.lastname: Rosini
authors.forename: Monia
authors.initials: M
authors.lastname: Lenzi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Ferruzzi
authors.forename: Eleonora
authors.initials: E
authors.lastname: Turrini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Hrelia
authors.forename: Piero
authors.initials: P
authors.lastname: Sestili
authors.forename: Cinzia
authors.initials: C
authors.lastname: Calcabrini
authors.forename: Carmela
authors.initials: C
authors.lastname: Fimognari
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D002470:Cell Survival; D004273:DNA, Neoplasm / Q000037:antagonists & inhibitors / Q000737:chemistry; D003959:Diamines / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D019075:Electrophoresis, Capillary / Q000379:methods; D006801:Humans; D020128:Inhibitory Concentration 50; D019169:Jurkat Cells; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000737:chemistry; D009690:Nucleic Acid Conformation; D011073:Polyamines / Q000008:administration & dosage*; D020871:RNA Stability; D012334:RNA, Neoplasm / Q000037:antagonists & inhibitors* / Q000737:chemistry; D013096:Spermine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D003959:Diamines; D011073:Polyamines; D012334:RNA, Neoplasm; D013096:Spermine; C054938:methoctramine